azacitidine has been researched along with Neoplasms, Cystic, Mucinous, and Serous in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bowden, NA; van der Westhuizen, A; Wong-Brown, MW | 1 |
1 other study(ies) available for azacitidine and Neoplasms, Cystic, Mucinous, and Serous
| Article | Year |
|---|---|
Sequential azacitidine and carboplatin induces immune activation in platinum-resistant high-grade serous ovarian cancer cell lines and primes for checkpoint inhibitor immunotherapy.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Carboplatin; Cell Growth Processes; Cell Line, Tumor; DNA Methylation; Female; Humans; Immune Checkpoint Inhibitors; Immunity; Neoplasm Grading; Neoplasms, Cystic, Mucinous, and Serous; Ovarian Neoplasms; Signal Transduction; Up-Regulation | 2022 |